The Rosenfeld group develops molecular diagnostic tools for cancer detection, characterisation and monitoring, to help make more informed treatment decisions. We focus on liquid biopsies, in which we analyse blood samples to detect and characterise cell-free circulating tumour DNA (ctDNA).
My research focuses on molecular pathology of pancreatic cancer, in particular its development and progression. We are using this knowledge to develop biomarkers for early, non-invasive detection of this malignancy in urine specimens.
We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.